Can an adult with metastatic castration‑resistant prostate cancer and normal liver function safely take abiraterone acetate 1000 mg daily with prednisone 5 mg daily and olaparib (Lynparza) 300 mg twice daily?

Yes, this combination is FDA-approved and can be safely taken together with appropriate monitoring.

The combination of abiraterone acetate 1000 mg daily with prednisone 5 mg daily and olaparib 300 mg twice daily is specifically FDA-approved for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). 1

FDA-Approved Dosing Regimen

The FDA label for olaparib (Lynparza) explicitly states:

• Olaparib: 300 mg orally twice daily
• Abiraterone: 1000 mg orally once daily (when used with olaparib)
• Prednisone or prednisolone: 5 mg orally twice daily 1

Note the FDA specifies prednisone 5 mg twice daily (total 10 mg/day) when combined with olaparib, not once daily as you mentioned. This differs from the standard abiraterone monotherapy dosing where prednisone 5 mg twice daily is also used 2.

Key Administration Requirements

Abiraterone must be taken on an empty stomach (no food 2 hours before and 1 hour after), while olaparib can be taken with or without food 2, 1. Both should be swallowed whole with water—do not crush or chew 2, 1.

Patients must continue androgen deprivation therapy (GnRH analog) concurrently or have had bilateral orchiectomy 1.

Clinical Evidence Supporting This Combination

The PROpel trial demonstrated that olaparib plus abiraterone significantly improved radiographic progression-free survival in BRCA-mutated mCRPC 3, 4. Real-world data from France involving 154 patients confirmed the combination's safety profile matches clinical trial data, with no new safety signals 4.

Recent network meta-analysis shows that for BRCA-mutated mCRPC specifically, olaparib combined with abiraterone significantly improved both PFS (HR = 0.61,95% CrI = 0.41-0.91) and OS (HR = 0.41,95% CrI = 0.21-0.80) compared to olaparib alone 5.

Critical Monitoring Requirements

Monthly monitoring is essential, especially initially 6:

• Liver function tests (AST, ALT, bilirubin) - monthly initially, then as clinically indicated
• Blood pressure - monthly minimum due to mineralocorticoid excess risk from abiraterone
• Potassium and phosphate levels - monthly minimum
• Complete blood count - monitor for anemia, neutropenia, thrombocytopenia from olaparib

Common Adverse Events to Anticipate

From the combination 3, 4:

• Anemia (most common, 43.3% in real-world data) - may require dose reduction or transfusion
• Fatigue (very common with both agents)
• Hypertension and hypokalemia (from abiraterone's mineralocorticoid effects)
• Nausea (from olaparib)
• Liver enzyme elevations (from abiraterone)

Dose Modification Algorithm

For hepatotoxicity (ALT/AST >5× ULN or bilirubin >3× ULN) 2:

1. Interrupt abiraterone
2. Resume at 750 mg daily when LFTs normalize
3. If recurs, reduce to 500 mg daily
4. If recurs again, discontinue permanently

For olaparib-related adverse events 1:

1. First reduction: 250 mg twice daily
2. Second reduction: 200 mg twice daily
3. Consider discontinuation if intolerable at lowest dose

Important Contraindication

Do not use this combination in patients with severe hepatic impairment (Child-Pugh Class C) 2. For moderate hepatic impairment (Child-Pugh Class B), reduce abiraterone to 250 mg once daily with weekly LFT monitoring for the first month 2.

MDS/AML Risk Warning

The cumulative incidence of myelodysplastic syndrome/acute myeloid leukemia with olaparib is approximately 1.2%, with 54% fatal outcomes 1. This risk is higher in patients previously treated with platinum agents or radiotherapy. Median time to MDS/AML development is approximately 2 years 1.